$VRDN filed an 8-K with results (Item 2.02) at 7:11 AM ET on Wed, Nov 4.
Vote
VRDN
Viridian Therapeutics, Inc.$26.62CS band Caution
+1.47 (+5.86%) TodayNov 4, 10:43 AM ET
About VRDN
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Why it moved
BioPharmaWatch reported Lumvoa's successful early launch in TED · earnings per 8-K
Sources: BioPharmaWatch
AI generated · Not investment advice
Why it moved
BioPharmaWatch reported Lumvoa's successful early launch in TED · earnings per 8-K
Confirmed: from the company’s own release or SEC filing.
Sources: BioPharmaWatch
Written 8:31 AM ET · last check 10:30 AM ET
AI generated · May contain errors · Not investment adviceSummarized from public reports · Sources linkedSign up free to see this.
Analysts
All ›Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.
Sentiment
No sentiment yet
Votes and Bull · Bear posts, 24h. At least 5 are needed.
How do you feel about VRDN?
Board · 0 threads
Open board ›Community opinions, not advice. Posts with a target get a receipt. How receipts work ›